Amarin Corporation plc AMRN
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -13.68%
- 1 year
- -23.05%
- Market cap
- 506.61M
- Revenue (ttm)
- 241.02M
- Profit margin
- -16.33%
- EPS (ttm)
- -0.80
- Shares out
- 411.34M
- Forward P/E
- -2.17
- YTD return
- -13.68%
- 1-year return
- -23.05%
- Volume
- 91.64K
- Avg volume
- 68.89K
- Open
- 12.05
- Previous close
- 12.13
- Day's range
- 11.87 – 12.17
- 52-week range
- 11.25 – 17.31
- Beta
- 1.93
- Analysts
- Underperform
- Price target
- 1.00 (-91.7%)
YTD -1.67 (-12.17%)
Key statistics
- Enterprise value
- -108.30M
- PEG ratio
- 0.00
- Price / sales
- 0.78
- Price / book
- 0.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -36.00%
- Free cash flow
- -17.89M
- Total cash
- 305.73M
- Total debt
- 8.21M
- Return on equity
- -7.26%
- Short % of float
- 4.42%
- 50-day average
- 0.5324
- 200-day average
- 0.70385
Analyst view
Consensus: underperform
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell2
Next earnings
Consensus EPS estimate -0.03.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 31, 2024 | Jun 1, 2024 | — | 0.01 | +0.06 | +120.00% |
| Feb 29, 2024 | Dec 1, 2023 | — | 0.00 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 20, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Jun 18, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Oct 25, 2023 | Jefferies | down | Buy | Hold |
| Jul 20, 2023 | Goldman Sachs | main | Sell | Sell |
| Jul 19, 2023 | Northland Capital Markets | main | Market Perform | Market Perform |
| Jan 6, 2023 | Jefferies | up | Hold | Buy |
About Amarin Corporation plc
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Ireland
- Website
- amarincorp.com
News
Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark 
Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript 
What Amarin (AMRN) Said on Its Q3 Earnings Call 
Amarin Corp Q3 2026 Earnings Call Transcript 
Amarin Corp Q3 Adj. EPS $0.08 Beats $(0.02) Estimate, Sales $39.550M Miss $43.711M Estimate 
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income 
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM) 
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026 
Head-To-Head Survey: Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX) 
Analyzing Amarin (NASDAQ:AMRN) & Elanco Animal Health (NYSE:ELAN)
Your note
Sign in to keep a note on AMRN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERG AARON D. | Chief Executive Officer | Purchase | Aug 1, 2024 | 805,380 |
| HOLT PATRICK | Chief Executive Officer | Purchase | Jan 21, 2024 | 314,426 |
| KETCHUM STEVEN B | Officer | Conversion of Exercise of derivative security | Jul 30, 2024 | 670,840 |
| MIKHAIL KARIM | Chief Executive Officer | Stock Award(Grant) | Feb 20, 2023 | 283,507 |
| REILLY THOMAS CHARLES | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 30, 2024 | 94,305 |
| WOLD OLSEN PER | Director | Conversion of Exercise of derivative security | Jan 9, 2023 | 171,027 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sarissa Capital Management, LP | 25.15% | 24,850,623 | 11.35M | Sep 29, 2024 |
| Kynam Capital Management, LP | 12.57% | 12,414,628 | 5.67M | Sep 29, 2024 |
| Eversept Partners, LP | 3.35% | 3,309,309 | 1.51M | Sep 29, 2024 |
| Morgan Stanley | 2.58% | 2,545,752 | 1.16M | Sep 29, 2024 |
| SCP Investment, LP | 2.53% | 2,500,000 | 1.14M | Sep 29, 2024 |
| Two Sigma Investments, LP | 2.41% | 2,380,016 | 1.09M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR Portfolio Developed World ex-US ETF | 0.25% | 247,507 | 113.04K | Sep 29, 2024 |
| Delaware Group Equity Fds IV-Delaware Healthcare Fund | 0.19% | 190,000 | 86.77K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.15% | 147,010 | 67.14K | Oct 30, 2024 |
| SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF | 0.14% | 135,261 | 61.77K | Sep 29, 2024 |
| Invesco ETF Tr II-Invesco NASDAQ Future Gen 200 ETF | 0.07% | 70,675 | 32.28K | Oct 30, 2024 |
| Blackstone Alternative Multi-Strategy Fund | 0.04% | 35,535 | 16.23K | Sep 29, 2024 |